Session Information
2008 Midyear Clinical Meeting
Click here to go to the previous page
The Great Debate! Pros and Cons of Erythropoietin Use
Track:
Educational Sessions
Program Code: 284-L01
Date: Monday, December 8, 2008
Time: 4:00 PM to 5:00 PM EST
Location:
W103
MEETING PLANNING ASSOCIATE:
Dr. Lauren Decloe, PharmD, The Johns Hopkins Hospital
PRESENTER(S):
Dr. Lauren Decloe, PharmD, The Johns Hopkins Hospital
Rowena Schwartz
- Describe the data that supports the role of ESA in improvement of quality of life indicators in individuals with chemotherapy-associated anemia.
- Discuss the evidence of venothromboembolic events (VTE) with the use of erythropoietic stimulating agents (ESA).
- Identify clinical scenario(s) where ESA use is appropriate for individuals with cancer and cancer-treatment related anemia.
- Summarize the current evidence that implicates ESA in tumor progression and it's applicability of this evidence in specific patient populations.